Oncopeptides AB (OSTO:ONCO) Gross Margin % : 91.75% (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Oncopeptides AB's Gross Profit for the three months ended in Sep. 2024 was kr7.81 Mil. Oncopeptides AB's Revenue for the three months ended in Sep. 2024 was kr8.51 Mil. Therefore, Oncopeptides AB's Gross Margin % for the quarter that ended in Sep. 2024 was 91.75%.

The historical rank and industry rank for Oncopeptides AB's Gross Margin % or its related term are showing as below:

OSTO:ONCO' s Gross Margin % Range Over the Past 10 Years
Min: 55.09 Med: 99.93 Max: 103.06
Current: 89.96

During the past 10 years, the highest Gross Margin % of Oncopeptides AB was 103.06%. The lowest was 55.09%. And the median was 99.93%.

OSTO:ONCO's Gross Margin % is ranked better than
85.94% of 747 companies
in the Biotechnology industry
Industry Median: 60.58 vs OSTO:ONCO: 89.96

Oncopeptides AB had a gross margin of 91.75% for the quarter that ended in Sep. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Oncopeptides AB was 0.00% per year.

Oncopeptides AB Gross Margin % Historical Data

The historical data trend for Oncopeptides AB's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB Gross Margin % Chart

Oncopeptides AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

55.09

99.93

103.06

Oncopeptides AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Gross Margin %	Get a 7-Day Free Trial															167.59	85.37	94.32	88.39	91.75

Competitive Comparison of Oncopeptides AB's Gross Margin %

For the Biotechnology subindustry, Oncopeptides AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncopeptides AB's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's Gross Margin % falls into.

Oncopeptides AB Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Oncopeptides AB's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	36.3	/	35.22
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(35.22 - -1.079)	/	35.22
	=	103.06 %

Oncopeptides AB's Gross Margin for the quarter that ended in Sep. 2024 is calculated as

Gross Margin % (Q: Sep. 2024 )	=	Gross Profit (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	7.8	/	8.507
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(8.507 - 0.702)	/	8.507
	=	91.75 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Oncopeptides AB (OSTO:ONCO) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Oncopeptides AB had a gross margin of 91.75% for the quarter that ended in Sep. 2024 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Oncopeptides AB Gross Margin % Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncopeptides AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (OSTO:ONCO) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

0RN4:UK OND:Germany

Address

Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53

Website

https://www.oncopeptides.com

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.